Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04436276 · ClinicalTrials.gov registry record · Phase 1
A Study of Ad26.COV2.S in Adults (COVID-19)
A Phase 1 study, sponsored by Janssen Vaccines & Prevention B.V..
- Completed
- Registry status
- Phase 1
- Development phase
- 1,085
- Enrollment target
NCT04436276: Completed Phase 1 study, sponsored by Janssen Vaccines & Prevention B.V..
NCT04436276 is a Phase 1 study that has completed, run by Janssen Vaccines & Prevention B.V.. The registered enrollment target is 1,085 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (1708% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04436276, a Phase 1 study, has completed, sponsored by Janssen Vaccines & Prevention B.V..
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 1,085 participants
- Enrollment target
Study Summary
The purpose of the study is to assess the safety, reactogenicity, and immunogenicity of Ad26.COV2.S at 2 dose levels, administered intramuscularly (IM) as a single-dose or 2-dose schedule, with a single booster vaccination administered in one cohort in healthy adults aged greater than or equal to (\>=) 18 to less than or equal to (\<=) 55 years and in adults aged \>= 65 years in good health with or without stable underlying conditions. The purpose of the study is also to assess the safety and reactogenicity of Ad26.COV2.S administered as ad hoc booster vaccination in healthy adults aged \>= 18 to \<= 55 years and in adults \>= 65 years in good health with or without stable underlying conditions.
Primary Outcome
Number of participants with solicited local AEs for 7 days after vaccination 1 in Cohorts 1a and 1b were reported. An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study. Solicited local (injection site) AEs that included injection site pain/tenderness, erythema and swelling at the study vaccine injection site, are used to assess the reactogenicity of the
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL Ad26.COV2.S
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,085 participants |
| Start Date | 2020-07-15 |
| Est. Completion | 2023-02-21 |
| Phase | Phase 1 |
What the finished NCT04436276 record still lists
NCT04436276 is an interventional study that assigns participants to a tested intervention. Its 1,085 participants enrollment target places it among the larger protocols in the corpus, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (1708% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04436276 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04436276 about?
NCT04436276 is a clinical study titled "A Study of Ad26.COV2.S in Adults (COVID-19)". The purpose of the study is to assess the safety, reactogenicity, and immunogenicity of Ad26.COV2.S at 2 dose levels, administered intramuscularly (IM) as a single-dose or 2-dose schedule, with a single booster vaccination administered in one cohort in healthy adults aged greater than or equal to (\...
What is the current status of trial NCT04436276?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 1,085 participants. The study started on 2020-07-15. Estimated completion is 2023-02-21.
What interventions are being tested in trial NCT04436276?
The interventions under investigation include: Placebo (BIOLOGICAL), Ad26.COV2.S (BIOLOGICAL).
Who is sponsoring clinical trial NCT04436276?
This trial is sponsored by Janssen Vaccines & Prevention B.V., which has 34 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04436276's enrollment target sits among peer trials
1,085 6th of 2000 higher than 1,995 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06671483 · 1,088 participants · Phase 3
A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have Not Taken Biologic Medicines
- NCT06074068 · 1,080 participants · NA
Father-Focused Intervention for Reducing Family Violence and Symptoms in Children
- NCT07213804 · 1,080 participants · Phase 3
A Two-Part Phase 3 Study of Sofetabart Mipitecan (LY4170156) in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Part B) Ovarian Cancer
- NCT07196722 · 1,092 participants · Phase 2
A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI